<DOC>
	<DOCNO>NCT01658501</DOCNO>
	<brief_summary>Primary objective : The primary objective study define dose response Glymera measure change baseline hemoglobin A1c ( HbA1c ) follow 20 week once-weekly dosing . Secondary objective : The secondary objective : - Describe incidence , severity , duration report gastrointestinal side effect Glymera compare active comparator ; - Compare change baseline HbA1c follow 20 week dose compare placebo active comparator ; - Compare change baseline fast plasma glucose ( FPG ) follow 20 week dose compare placebo active comparator ; - Describe frequency adverse event treatment group ; - Describe endpoint follow subgroup subject accord baseline type 2 diabetes mellitus ( T2DM ) therapy : diet exercise , metformin , sulfonylurea , metformin sulfonylurea combination therapy .</brief_summary>
	<brief_title>Phase 2b Multicenter , Randomized , Double-Blind , Placebo- Active-Controlled , Parallel-Group Study Assess PD Response Safety Three Dose Levels ( PB1023 ) Injection Following 20 Weeks Weekly SC Dosing Adults With T2DM</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Male female subject 18 75 year age , inclusive ; Body mass index ≤45 kg/m2 ; Diagnosed T2DM HbA1c ≥7.0 % ≤11.0 % treat diet exercise alone , stable dos metformin alone , sulfonylurea alone metformin sulfonylurea . Currently take take within last 6 month nonoral antihyperglycemic agent ( eg , insulin , Byetta® , Bydureon® , Victoza ) . Shortterm use insulin within period cause exclusion insulin use treatment acute intercurrent illness ; Known allergy serious adverse effect cause approved investigational glucagonlike peptide1 ( GLP1 ) receptor analog/agonist ; Unstable cardiovascular disease ; History weight loss surgery gastrointestinal surgical procedure could possibly interfere mechanism action GLP1 receptor agonist ; Based contraindications/warnings identify GLP1 receptor agonist , subject exclude : History , symptom , sign pancreatitis severe gastrointestinal disease ( ie , gastroparesis ) Personal family history medullary thyroid tumor history Multiple Endocrine Neoplasia Syndrome Type 2 ; Clinically significant renal and/or hepatic dysfunction ; Pregnant lactate female subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>